Grant: CIHR Fellowship
Direct Payment
$150,000.00
Investigating the ability of B cells to cross-prime cytotoxic killer T cells
EF 2009-10
Résumé
Professional antigen presenting cells are comprised of dendritic cells (DCs), macrophages and B cells. All three of these cell types have the ability to efficiently engage T cells, however, they differ in their ability to acquire antigen and process it into peptides for presentation to T cells. DCs and macrophages efficiently acquire antigen through endocytosis, but only DCs have endogenous pathways for cross-presentation of antigens to cytotoxic killer T cells. On the other hand, B cells are not as specialized at taking up material through endocytosis but can take up antigen through the B cell receptor and yet uptake of antigen alone is not sufficient for cross-priming cytotoxic killer T cells. New findings suggest that B cells are able to cross-present to T cells provided that secondary signals are supplied to activate cross-priming. Signaling pathways stemming from the activation of toll-like receptors (TLR) are one promising possibility to act as a necessary requirement. This project aims to develop a methodology to deliver antigen and TLR agonists specifically to B cells in vivo for the purposes of studying the ability of B cells to cross-prime cytotoxic killer T cells. Specifically, CD22, a B cell-specific marker, will be targeted using high affinity ligands that initiate endocytosis of CD22 and associated cargo. In such a manner, the requirement of TLR signaling pathways can be investigated systematically. This research will shed light on a fundamental aspect of the immune system while providing a tool that can be used for rational vaccine development and investigating many other aspects of B cell function in vivo.
Programme
CIHR Fellowship
Bénéficiaire
Emplacement
California, United States of America
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
193195
Name
Macauley Matthew S
Region
California
Country
United States of America
Orgtype
Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Investigating the ability of B cells to cross-prime cytotoxic killer T cells
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
B Cells; Cross-Presentation; Cytotoxic T Cells; Flow Cytometry; Glycobiology; Immunology; Lectins; Liposomes; Siglecs; Vaccine
Abstract
Professional antigen presenting cells are comprised of dendritic cells (DCs), macrophages and B cells. All three of these cell types have the ability to efficiently engage T cells, however, they differ in their ability to acquire antigen and process it into peptides for presentation to T cells. DCs and macrophages efficiently acquire antigen through endocytosis, but only DCs have endogenous pathways for cross-presentation of antigens to cytotoxic killer T cells. On the other hand, B cells are not as specialized at taking up material through endocytosis but can take up antigen through the B cell receptor and yet uptake of antigen alone is not sufficient for cross-priming cytotoxic killer T cells. New findings suggest that B cells are able to cross-present to T cells provided that secondary signals are supplied to activate cross-priming. Signaling pathways stemming from the activation of toll-like receptors (TLR) are one promising possibility to act as a necessary requirement. This project aims to develop a methodology to deliver antigen and TLR agonists specifically to B cells in vivo for the purposes of studying the ability of B cells to cross-prime cytotoxic killer T cells. Specifically, CD22, a B cell-specific marker, will be targeted using high affinity ligands that initiate endocytosis of CD22 and associated cargo. In such a manner, the requirement of TLR signaling pathways can be investigated systematically. This research will shed light on a fundamental aspect of the immune system while providing a tool that can be used for rational vaccine development and investigating many other aspects of B cell function in vivo.
Competitiondate
200910
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Macauley, Matthew S
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $150,000~ $0~